Biomatter, a protein design company engineering next-generation enzymes, announced the appointment of Cindy Chang, PhD, MBA, as Vice President of Business Development, Biopharma. In her new role, Chang will spearhead partnerships and commercial strategy across diagnostics and pharmaceutical manufacturing. She will also strengthen the company’s position as a partner of choice for global biopharma innovators.
Driving Strategic Growth in Biopharma
As Vice President, Chang will focus on connecting Biomatter’s data-driven enzyme design engine with biopharma and diagnostic teams worldwide. Her leadership will be instrumental in expanding the company’s collaborative ecosystem, bringing customized, high-performance enzyme solutions to market faster. With over 15 years of scientific and commercial experience, Chang has built a distinguished career in enzymology and biomanufacturing. Before joining Biomatter, she held key positions at Prospect Bio, Codexis, and Ginkgo Bioworks. At these companies, she led initiatives that bridged innovation with commercial success. She holds a PhD in Biochemistry from the University of California, Berkeley, and an MBA from the Haas School of Business.
Harnessing AI-Powered Enzyme Design
At Biomatter, Chang will help align customer needs with bespoke enzyme solutions developed using the company’s proprietary Intelligent Architecture™ platform. This platform integrates advanced AI models with rapid experimental screening, enabling the creation of enzymes with novel functions, enhanced selectivity, and improved stability. Biomatter’s custom-designed enzymes address critical needs across pharma and diagnostics. They enable challenging chemistries in active pharmaceutical ingredient (API) manufacturing and enhance biomarker detection in complex diagnostic applications.
Leadership Perspectives
Cindy Chang, Vice President of Biopharma Business Development at Biomatter stated, “Biomatter is engineering truly unique enzymes that unlock the creation of new medicines and enable next-generation diagnostics. I’m thrilled to join the team and collaborate with innovators across pharma and biotech to turn bold chemistry and biomarker ideas into real-world breakthroughs.”
Laurynas Karpus, Co-founder & CEO of Biomatter, added, “Cindy brings an exceptional combination of scientific depth and commercial expertise. She bridges the gap between breakthrough product ideas and our enzyme design technology that transforms them into practical solutions for biopharma teams globally. We’re thrilled to have her on board.”
Strengthening Innovation in Biopharma and Diagnostics
Chang’s appointment comes at a pivotal time as Biomatter accelerates multiple projects in biopharma and diagnostics. The company continues to push the boundaries of enzyme engineering by integrating machine learning, automation, and molecular biology—unlocking new frontiers in biomanufacturing, therapeutic development, and diagnostic innovation. The press release states that Cindy Chang is now leading Biomatter. Under her leadership, the company will deepen its partnerships and scale its technology. It will also deliver transformative enzyme solutions to the global life sciences community.
Cindy Chang, VP of Biopharma Business Development at Biomatter.
